- Home
- PK vs APLS Comparison
PK vs APLS Comparison
Compare PK & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- APLS
- Stock Information
- Founded
- PK 1946
- APLS 2009
- Country
- PK United States
- APLS United States
- Employees
- PK N/A
- APLS N/A
- Industry
- PK Real Estate Investment Trusts
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- PK Real Estate
- APLS Health Care
- Exchange
- PK Nasdaq
- APLS Nasdaq
- Market Cap
- PK 2.5B
- APLS 2.3B
- IPO Year
- PK N/A
- APLS 2017
- Fundamental
- Price
- PK $10.42
- APLS $17.70
- Analyst Decision
- PK Buy
- APLS Buy
- Analyst Count
- PK 11
- APLS 18
- Target Price
- PK $15.15
- APLS $39.71
- AVG Volume (30 Days)
- PK 4.8M
- APLS 2.7M
- Earning Date
- PK 05-05-2025
- APLS 05-07-2025
- Dividend Yield
- PK 9.61%
- APLS N/A
- EPS Growth
- PK 45.67
- APLS N/A
- EPS
- PK 0.61
- APLS N/A
- Revenue
- PK $2,602,000,000.00
- APLS $775,839,000.00
- Revenue This Year
- PK $2.76
- APLS $12.25
- Revenue Next Year
- PK $3.39
- APLS $21.08
- P/E Ratio
- PK $17.09
- APLS N/A
- Revenue Growth
- PK N/A
- APLS 48.04
- 52 Week Low
- PK $8.27
- APLS $16.65
- 52 Week High
- PK $16.58
- APLS $43.99
- Technical
- Relative Strength Index (RSI)
- PK 54.29
- APLS 36.61
- Support Level
- PK $9.89
- APLS $16.65
- Resistance Level
- PK $10.43
- APLS $20.75
- Average True Range (ATR)
- PK 0.33
- APLS 1.11
- MACD
- PK 0.12
- APLS 0.24
- Stochastic Oscillator
- PK 87.08
- APLS 28.29
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.